Efficacy and Safety of Efalizumab in the Treatment of Moderate-Severe Hydradenitis Suppurativa

Inclusion Criteria: * Female between 18-65 years of age * Has Hydradenitis Suppurativa (HS) involving at least 1 area of the body with greater than or equal to 12 lesions; onset of disease is 6 months and greater. * Failed at least 3 months of standard conventional therapies such as antibiotics and/or systemic retinoids * Willing to use contraception unless not of childbearing potential * Able to comply with protocol requirements Exclusion Criteria: * Received within 4 weeks prior immunosuppressive medication * Received treatment within 3 months prior with systemic retinoids (acitretin or isotretinoin) * Received high potency (class I or II) topical corticoid steroids, topical antibiotics, systemic antibiotics, or topical immunomodulators (tacrolimus or pimecrolimus) within 2 weeks prior to baseline visit * Received intralesional injections of corticosteroids within 4 weeks prior * Received surgical intervention for the treatment of HS * Known history of HIV seropositivity * History of untreated or active tuberculosis * Active infection requiring systemic antibiotics within 4 weeks of baseline visit * History of recurrent/chronic infections * History of malignancy within 5 years of baseline visit (except for squamous cell carcinoma or basal cell carcinoma; may enroll if treated and assessed as cured). * Pregnant or breastfeeding * Immunocompromised due to a medical condition * Has any significant laboratory abnormalities * Has any medical condition that may interfere with evaluation of the safety and efficacy of efalizumab * Received efalizumab or any other biologic within the last 6 months * Taken or used any investigational drug or device within 30 days prior